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Porcine circovirus type 2 (PCV2) is associated with postweaning multisystemic wasting syndrome in pigs,
whereas PCV1 is nonpathogenic. We previously demonstrated that a chimeric PCV1-2 virus (with the immu-
nogenic capsid gene of PCV2 cloned into the backbone of PCV1) induces an antibody response to the PCV2
capsid protein and is attenuated in pigs. Here, we report that the attenuated chimeric PCV1-2 induces
protective immunity to wild-type PCV2 challenge in pigs. A total of 48 specific-pathogen-free piglets were
randomly and equally assigned to four groups of 12 pigs each. Pigs in group 1 were vaccinated by intramuscular
injection with 200 g of the chimeric PCV1-2 infectious DNA clone. Pigs in group 2 were vaccinated by
intralymphoid injection with 200 g of a chimeric PCV1-2 infectious DNA clone. Pigs in group 3 were
vaccinated by intramuscular injection with 103.5 50% tissue culture infective doses (TCID50) of the chimeric
PCV1-2 live virus. Pigs in group 4 were not vaccinated and served as controls. By 42 days postvaccination
(DPV), the majority of pigs had seroconverted to PCV2 capsid antibody. At 42 DPV, all pigs were challenged
intranasally and intramuscularly with 2  104.5 TCID50 of a wild-type pathogenic PCV2 virus. By 21 days
postchallenge (DPC), 9 out of the 12 group 4 pigs were viremic for PCV2. Vaccinated animals in groups 1 to
3 had no detectable PCV2 viremia after challenge. At 21 DPC the lymph nodes in the nonvaccinated pigs were
larger (P < 0.05) than those of vaccinated pigs. The PCV2 genomic copy loads in lymph nodes were reduced
(P < 0.0001) in vaccinated pigs. Moderate amounts of PCV2 antigen were detected in most lymphoid tissues
of nonvaccinated pigs but in only 1 of 36 vaccinated pigs. Mild-to-severe lymphoid depletion and histiocytic
replacement were detected in lymphoid tissues in the majority of nonvaccinated group 4 pigs but in only a few
vaccinated group 1 to 3 pigs. The data from this study indicated that when given intramuscularly in pigs, the
attenuated chimeric PCV1-2 live virus, as well as the chimeric PCV1-2 infectious DNA clone, induces protective
immunity against PCV2 infection and could potentially serve as an effective vaccine.
Postweaning multisystemic wasting syndrome (PMWS) was
first observed in piglets of a high-health herd in Canada in 1991
(14). Since then PMWS has been reported in many pig-pro-
ducing regions of North America, Europe, and Asia (2, 5, 6, 21,
28). The primary causative agent of PMWS is thought to be
type 2 porcine circovirus (PCV2) (2, 7, 9, 10, 15, 20, 29).
The type 1 porcine circovirus (PCV1) was initially discov-
ered as a persistent contaminant of a porcine kidney cell cul-
ture (PK-15) (36). PCV1 is a small nonenveloped icosahedral
virus, with a single-stranded circular DNA genome of about
1.76 kb. PCV1 has not been found to cause disease and is
generally considered to be nonpathogenic (1, 35). Pathogenic
PCV2 and nonpathogenic PCV1 share only about 76% nucle-
otide sequence identity but have similar genomic organizations
(10). Two open reading frames (ORFs) have been character-
ized: ORF1 encodes rep proteins required for viral replication
(4) and ORF2 encodes the immunogenic capsid protein (25).
Both PCV1 and PCV2 are members of the Circoviridae family,
along with psittacine beak and feather disease virus (3) and the
tentative members columbid circovirus, goose circovirus, and
canary circovirus (23, 31, 37). The human circoviruses TT vi-
rus, TT virus-like minivirus, and the SEN virus have genomic
organization similar to that of PCV (27, 34, 38).
Accumulated evidence indicates that PCV2 is the primary,
but not the sole, causative agent of PMWS (2, 7, 9, 10, 15, 20,
29, 30). Clinical PMWS has been reproduced in conventional
pigs coinfected with PCV2 and either porcine parvovirus or
porcine reproductive and respiratory syndrome virus (PRRSV)
(15, 29). Ladekjaer-Mikkelsen et al. (20) recently reproduced
PMWS in 3-week-old specific-pathogen-free (SPF) piglets in-
oculated with PCV2 alone. PMWS was also reproduced in
PCV2-inoculated piglets immunostimulated with keyhole lim-
pet hemocyanin in incomplete Freund’s adjuvant (18).
Opriessnig et al. (30) showed that pigs vaccinated with Myco-
plasma hyopneumoniae and Actinobacillus pleuropneumoniae
prior to PCV2 inoculation had increased length of PCV2 vire-
mia and more-severe lymphoid lesions compared to unvacci-
nated pigs. It is generally believed that immunostimulation
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either by vaccination or secondary viral infection plays a role in
the occurrence of PMWS (12, 17, 18, 19). However, the exact
role of immunostimulation in the progression to clinical
PMWS is not known.
There is a need for a vaccine to prevent PCV2 infections and
its role in the progression to clinical PMWS. We previously
showed that a chimeric PCV1-2 infectious DNA clone (with
the immunogenic capsid gene of PCV2 cloned into the back-
bone of the nonpathogenic PCV1) is infectious when injected
directly into the lymph nodes of SPF piglets and induces a
strong antibody response to PCV2 capsid antigen while re-
maining attenuated in pigs (11). Therefore, chimeric PCV1-2
appears to be a good candidate vaccine. In this study, we
evaluated the efficacy of this candidate vaccine by subjecting
SPF pigs to intramuscular and intralymphoid immunization
with chimeric PCV1-2 virus and an infectious chimeric PCV1-2
DNA clone followed by challenge with wild-type pathogenic
PCV2. We showed that the PCV1-2 chimeric virus and the
infectious DNA clone both induce protective immunity against
wild-type PCV2 challenge in SPF pigs.
MATERIALS AND METHODS
PCV2 and chimeric PCV1-2 infectious DNA clones. The construction of PCV2
and the chimeric PCV1-2 infectious DNA clone was reported previously (9, 11).
The original wild-type PCV2 was from a pig with naturally occurring PMWS on
an Iowa farm (isolate 40895) (10). The PCV2 infectious DNA clone was con-
structed by cloning two tandem copies of the complete PCV2 genomes into
pBluescript vector. The PCV2 infectious DNA clone and the PCV2 virus gen-
erated by transfection of PK-15 cells with the PCV2 infectious DNA clone have
been shown to induce the hallmark pathological lesions of PMWS (9). The
chimeric PCV1-2 infectious DNA clone was constructed by replacing the ORF2
capsid gene of nonpathogenic PCV1 with that of PCV2 in the genomic backbone
of PCV1 (11). The PCV2 and PCV1-2 infectious clone plasmids used in this
study were prepared essentially as previously described (9, 11). The concentra-
tion of the plasmid DNA used in vaccination of pigs was determined by spec-
trophotometry.
Generation and infectivity titration of PCV1-2 and PCV2 virus stocks. PCV2
and chimeric PCV1-2 live viruses were generated by transfection of PK-15 cells
with the respective infectious DNA clone as previously described (9, 11). To
determine the infectivity titers of the PCV2 and chimeric PCV1-2 virus stocks,
PK-15 cells were cultivated on 8-well LabTek chamber slides (Nalge Nunc
International). When the PK-15 cells reached 70 to 80% confluency, the cells
were infected with a 10-fold serial dilution of either PCV2 or PCV1-2 virus stock.
After 3 days of incubation, the infected cells were stained in an immunofluores-
cence assay to determine the infectivity titers as previously described (9, 11).
Briefly, the infected cells were fixed to the LabTek chamber slides through the
use of an 80% acetone and 20% methanol fixing solution. Both PCV2- and
PCV1-2-infected cells were then incubated with PCV2 polyclonal rabbit anti-
body. After washing three times with phosphate-buffered saline buffer, the cells
were incubated with a secondary fluorescein isothiocyanate-labeled goat anti-
rabbit IgG antibody (KPL Inc., Gaithersburg, Md.). Slides were mounted using
Fluoromount-G and coverslipped. Viral infectivity titers were calculated using
the Ka¨rber method.
Vaccination of SPF pigs with a chimeric PCV1-2 infectious DNA clone as well
as PCV1-2 chimeric live virus. A total of 48 9-week-old SPF piglets were ran-
domly assigned to four groups of 12 pigs each, and each group was housed
separately. Pigs in group 1 were vaccinated with 200 g of chimeric PCV1-2
infectious DNA clone by intramuscular injection. Pigs in group 2 were vaccinated
with 200 g of chimeric PCV1-2 infectious DNA clone by intrasuperficial ingui-
nal lymph node injections. Pigs in group 3 were vaccinated with 103.5 50% tissue
culture infective doses of the chimeric PCV1-2 live virus by intramuscular injec-
tion. Pigs in group 4 were not vaccinated and served as controls. All animals were
monitored daily for clinical signs, and serum samples were collected at 1, 7, 14,
21, 28, 35, and 42 days postvaccination (DPV) and weekly on the appropriate
days postchallenge (DPC) until necropsies were performed at 21 DPC.
Challenge of vaccinated pigs with wild-type pathogenic PCV2. At 42 DPV, all
pigs were challenged with 2  104.5 50% tissue culture infective doses of the
wild-type pathogenic PCV2. To maximize the challenge conditions, each animal
received one-third of the PCV2 challenge inoculum intramuscularly and two-
thirds intranasally. All animals were subjected to necropsies at 21 DPC (63
DPV).
Clinical evaluation. Pigs were weighed at DPV 0 and at the time of necropsy.
Rectal temperatures and clinical respiratory scores ranging from 0 to 6 (0,
normal; 6, severe) (13) were recorded every other day from 1 to 63 DPV (21
DPC). Clinical observations, including evidence of central nervous system dis-
ease, icterus, musculoskeletal disease, and changes in body condition, were
recorded daily.
Gross pathology and histopathology. The necropsy team was blinded to the
vaccination status of the pigs at necropsy. Complete necropsies were performed
on all pigs at 21 DPC. On the basis of a previously described scoring system (13),
an estimated percentage of the lung with grossly visible pneumonia was recorded
for each pig. The degree of enlargement of lymph nodes (range: 0, normal size;
3, three times larger than normal) was estimated. Sections for histopathologic
examination were taken from lungs (five sections), heart, lymph nodes (tracheo-
bronchial, mediastinal, mesenteric, subiliac, and superficial inguinal), tonsil, thy-
mus, liver, spleen, small intestine, colon, pancreas, and kidney. The tissues were
examined in a blinded fashion, and each section was given a score for severity of
lung, lymph node, and liver lesions (13). Lung scores ranged from 0 (normal) to
6 (severe lymphohistiocytic interstitial pneumonia). Liver scores ranged from 0
(normal) to 3 (severe lymphohistiocytic hepatitis). Lymph nodes were scored for
the estimated amount of lymphoid depletion (LD) of follicles ranging from 0
(normal or no LD) to 3 (severe LD) and for the degree of histiocytic replacement
(HR) of follicles (0, none; 3, large amount) (13).
IHC. Immunohistochemistry (IHC) detection of PCV2-specific antigen was
performed on lymph node, spleen, tonsil, and thymus tissues collected during
necropsies at 21 DPC. A rabbit polyclonal antiserum against PCV2 was used for
IHC in accordance with procedures described previously (33). The amount of
PCV2 antigen distributed in the lymphoid tissues was scored in a blinded fashion
by assigning a score ranging from 0 for no signal to 3 for a strong positive signal.
Serology. Serum samples were collected from all pigs at 1, 7, 14, 21, 28, 35,
and 42 DPV and at 7, 14, and 21 DPC. Serum antibodies to PRRSV were assayed
using a Herd Check PRRSV enzyme-linked immunosorbent assay (ELISA)
(IDEXX Laboratories, Westbrook, Mass.). Serum antibodies to porcine parvo-
virus were detected by a hemagglutination inhibition assay (16). Serum antibod-
ies to PCV2 were detected by a modified indirect ELISA based on the recom-
binant ORF2 capsid protein of PCV2 (24). Serum samples with a sample/positive
(S/P) ratio above 0.20 were considered seropositive (24).
Quantitative real-time PCR assay. To determine virus genomic copy loads of
chimeric PCV1-2 and PCV2 in sera and tissues of vaccinated and challenged
swine, serum samples were tested with a quantitative real-time PCR (22) at 1,
7, 14, 21, 28, 35, and 42 DPV as well as at 7, 14, and 21 DPC. Briefly, a pair of
primers, MCV1 (5-GCTGAACTTTTGAAAGTGAGCGGG-3) and MCV2
(5-TCACACAGTCTCAGTAGATCATCCCA-3), was synthesized (10) and
used for the quantitative real-time PCR. The MCV1 and MCV2 primer pair was
designed to amplify known PCV1 and PCV2 sequences, including the chimeric
PCV1-2 sequence (11). Primers MCV1 and MCV2 amplify a 220-bp fragment
when chimeric PCV1-2 or PCV2 is used as a template. Viral DNA was extracted
from a 100-l serum sample or 50 g of homogenized tracheobronchial lymph
node (TBLN) tissues through the use of DNAzol reagent according to the
protocol of the manufacturer (Molecular Research Center, Cincinnati, Ohio).
The DNA extracted from serum samples was resuspended in 100 l of DNase–
RNase–proteinase-free water. The DNA extracted from TBLN tissues was re-
suspended in 300 l of DNase–RNase–proteinase-free water. The PCR was
performed in the presence of intercalating SYBR green dye (Molecular Probes
Inc., Eugene, Oreg.). The PCR parameters consisted of 38 cycles of denaturation
at 94°C for 15 s, annealing at 48°C for 15 s, and extension at 72°C for 30 s. To
quantify the viral genomic copy numbers, a standard dilution series with a known
amount of plasmid containing a single copy of the PCV2 genome (9) was run
simultaneously with samples in each reaction. After the reaction was completed,
a melt curve cycle was included to confirm the size of the PCR product. The
geometric mean of viral genomic copies per reaction on TBLN homogenates was
calculated for each group after setting results for negative samples to 1 copy per
sample.
PCR. DNA extracts from TBLNs of selected animals in each group were
amplified using PCR primer sets specific for PCV2 or PCV1-2. To amplify
chimeric PCV1-2-specific sequences, the PCR employed primer pair Gen.PCV1
(5-GTGGACCCACCCTGTGCC-3) and Orf.PCV2 (5-CAGTCAGAACGCC
CTCCTG-3) to amplify a fragment of 580 bp (11). To amplify PCV2-specific
sequences, the PCR employed primer pair Gen.PCV2 (5-CCTAGAAACAAG
TGGTGGGATG-3) and Orf.PCV2 (5-CAGTCAGAACGCCCTCCTG-3) to
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amplify a fragment of 900 bp (11). The PCR products were sequenced to confirm
the identity of the virus recovered from pigs.
Statistical analyses. All statistical analyses described below were performed
using an SAS system (version 8.02; SAS Institute Inc., Cary, N.C.). Serum sample
S/P ratios determined by ELISA were compared between vaccinated and non-
vaccinated groups by analysis of variance using the MIXED procedure. The
model included the effects of vaccine, DPV, and their interaction. Chimeric
PCV1-2 vaccination effects for each DPV were evaluated by the slice option. S/P
ratios were dichotomized to the presence or absence of seroconversion at S/P 
0.20 and analyzed by logistic regression using the LOGISTIC procedure. Mean
viral genomic copy loads in lymph nodes were compared by the Kruskal-Wallis
test using the NPAR1WAY procedure and/or by analysis of variance of ranked
data followed by a Bonferroni test of multiple mean ranks, using the GLM
procedure. Gross pathological and histopathologic lesion scores were compared
by the Kruskal-Wallis test with the NPAR1WAY procedure and/or by analysis of
variance using the GLM procedure followed by a Bonferroni test of multiple
means. The proportions of pigs with gross and histopathologic lesions in various
tissues were compared between groups by Fisher’s exact test, using the FREQ
procedure.
RESULTS
Chimeric PCV1-2 live virus and the chimeric PCV1-2 infec-
tious DNA clone both replicate in pigs when injected intra-
muscularly or intralymphoid and induce specific antibody re-
sponse against PCV2 capsid antigen. Prior to inoculation at
1 DPV, serum samples from all animals tested negative by
real-time PCR for PCV1 or PCV2 nucleic acids.
Group 1 pigs vaccinated intramuscularly with the chimeric
PCV1-2 DNA clone did not develop PCV1-2 viremia for the
duration of the study, as no PCV1-2 DNA was detected in sera
(Table 1). Three pigs in group 1 had detectable PCV2 maternal
antibody titers at 1 DPV; the titer levels waned by DPV 14.
Seroconversion to PCV2-specific antibodies occurred in 7 out
of 12 pigs by DPV 42, the day of challenge with wild-type
pathogenic PCV2 (Table 2).
Fenaux et al. have previously shown that pigs can be infected
by intralymphoid injection of PCV2 or PCV1-2 infectious
DNA clone (9, 11). Therefore, group 2 pigs were made positive
controls by vaccination through intralymphoid injection of the
chimeric PCV1-2 infectious DNA clone. Like the pigs in group
1, none of the vaccinated pigs in group 2 developed PCV1-2
viremia (Table 1). Of the 12 pigs, 3 had detectable PCV2
maternal antibody titers at DPV 1; the titer levels waned in
all by DPV 14. Seroconversion to PCV2 capsid antibodies was
first detected at DPV 21, and 7 of the 12 pigs had serocon-
verted by DPV 42 (Table 2).
Animals in group 3 were vaccinated with the chimeric
PCV1-2 live virus by intramuscular injection. PCV1-2 viremia
was not detected in any of the immunized pigs for the duration
of the study. Four pigs in group 3 had detectable maternal
PCV2 antibodies at 1 DPV; the titer levels waned in all by 7
DPV. Seroconversion to PCV2 capsid antibodies was first de-
tected at 28 DPV in 4 of the 12 animals, and by 42 DPV all pigs
in group 3 had seroconverted (Table 2).
PCV1-2 viremia was not detected in the nonvaccinated pigs
TABLE 1. Detection of chimeric PCV1-2 and PCV2 viremia by real-time PCR in sera of vaccinated and nonvaccinated pigs
Group Vaccine Route ofvaccination
No. of pigs with viremia/total on DPVa: Total
(PCV1-2)
No. of pigs with
viremia/total on DPCa,b Total
(PCV2)
2 7 14 21 28 35 42 7 14 21
1 PCV1-2 DNAc Intramuscular 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12
2 PCV1-2 DNA Intralymphoid 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12
3 PCV1-2 virusd Intramuscular 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12
4 None 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 1/12 9/12 4/12 9/12
a Results represent detection by real-time PCR of chimeric PCV1-2 and wild-type PCV2 nucleic acid.
b At 42 DPV, the animals in all four groups were challenged with the wild-type PCV2 virus.
c Cloned PCV1-2 genomic DNA in pSK plasmid.
d A PCV1-2 live vaccine virus stock generated by transfection of PK-15 cells with PCV1-2 infectious DNA clone.
TABLE 2. Seroconversion to PCV2-specific antibodies in pigs vaccinated with PCV1-2 live virus or with PCV1-2 infectious DNA clone
before and after PCV2 challenge
Group Vaccine Route ofvaccination
Maternal
antibodya
No. of pigs testing positive/total no. of pigs on DPVb:
No. of pigs testing
positive/total no. of
pigs on DPCb,c:
1 7 14 21 28 35 42 7 14 21
1 PCV1-2 DNAd Intramuscular No 0/9 0/9 1/9 1/9 1/9 1/9 6/9 8/9 9/9 9/9
Yes 3/3 1/3 0/3 0/3 0/3 2/3 1/3 2/3 2/3 2/3
2 PCV1-2 DNAd Intralymphoid No 0/9 0/9 0/9 1/9 2/9 5/9 5/9 8/9 9/9 8/9
Yes 3/3 1/3 0/3 1/3 1/3 2/3 2/3 3/3 3/3 3/3
3 PCV1-2 viruse Intramuscular No 0/8 0/8 0/8 0/8 2/8 6/8 8/8 7/8 8/8 8/8
Yes 4/4 0/4 0/4 0/4 2/4 3/4 4/4 4/4 4/4 4/4
4 None No 0/9 0/9 0/9 0/9 0/9 0/9 0/9 0/9 5/9 9/9
Yes 3/3 1/3 1/3 1/3 1/3 1/3 1/3 1/3 1/3 3/3
a Some animals in each group had maternal antibodies at 1 DPV.
b PCV2 antibody was measured with an ELISA with the recombinant PCV2 capsid antigen: results represent the number of pigs testing positive/number tested.
c At 42 DPV, the animals in all four groups were challenged with the wild-type PCV2 virus.
d Cloned chimeric PCV1-2 genomic DNA in pSK plasmid.
e PCV1-2 candidate vaccine live virus stock generated by transfection of PK-15 cells with the chimeric PCV1-2 infectious DNA clone.
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in group 4, and none of the animals seroconverted to PCV2
antibodies prior to PCV2 challenge (Table 1 and Table 2).
Three pigs in group 4 had detectable PCV2 maternal antibod-
ies at DPV 1. By DPV 7, the maternal antibody had waned
in all but one animal.
PCV2 antibody S/P ratios differed between treatment groups
(P  0.0001) and over time (P  0.0001) (data not shown).
Following vaccination, up to DPV 42 (the day of PCV2 chal-
lenge) pigs in groups 1, 2, and 3 were 1.9 (95% confidence
interval [CI] [0.7; 5.1]), 3.51 (95% CI [1.3; 9.1]), and 5.4 (95%
CI [2.0; 14.1]) times more likely to have an S/P ratio greater
than 0.20 than nonvaccinated pigs in group 4 (overall vaccine
effect; P  0.004).
The chimeric PCV1-2 candidate vaccine prevents PCV2 vire-
mia and reduces virus load in lymph nodes after challenge
with wild-type pathogenic PCV2. After the vaccinated pigs
were challenged with wild-type pathogenic PCV2, PCV2 vire-
mia was not detected by real-time PCR in any of the vaccinated
pigs in groups 1, 2, and 3 (Table 1). In group 4 nonvaccinated
pigs, PCV2 viremia was first detected at DPC 7 in 1 of the 12
pigs and 9 of the 12 pigs had detectable PCV2 viremia by 14
DPC (Table 1). Seroconversion to PCV2 antibodies was first
detected at DPC 14 in 6 of the 12 group 4 pigs, and by DPC 21
all pigs in group 4 had seroconverted to PCV2 (Table 2). The
PCV2 viral genome loads in serum samples of group 4 pigs
peaked at DPC 14; the loads ranged from 2,800 to 240,800
PCV2 genomic copies per ml of serum.
At necropsy (DPC 21), PCV2 genomic DNA was detected in
the tracheobronchial lymph nodes (TBLN) in 3 of 12 group 1
pigs, 2 of 12 group 2 pigs, 5 of 12 group 3 pigs, and 9 of 12
group 4 pigs (P  0.057) (Fig. 1). The range of PCV2 viral
genomic copy loads per 10 g of homogenized TBLN in pos-
itive-testing samples was 1,023 to 61,119 in group 1, 10,532 to
82,152 in group 2, 1,652 to 5,419,774 in group 3, and 363 to
621,285,534 in group 4 (Fig. 1). The median genomic copy
loads differed between groups 1, 2, 3, and 4 (P  0.012).
Median PCV2 copy loads in TBLN did not differ between
groups 1, 2, and 3 or between groups 3 and 4 (P  0.05);
however, loads did differ between groups 1 and 4 and between
groups 2 and 4 (P 0.05). PCR amplification using PCV2- and
PCV1-2-specific primers followed by DNA sequencing con-
firmed that the genomic sequence detected by real-time PCR
in the TBLN of animals in groups 1, 2, 3, and 4 originated from
the pathogenic PCV2 and not from the chimeric PCV1-2 vac-
cine virus.
The chimeric PCV1-2 candidate vaccine reduces macro-
scopic and microscopic lesions as well as viral antigen load in
tissues of vaccinated pigs after challenge with wild-type patho-
genic PCV2. (i) Clinical evaluation. Clinical signs characteris-
tic of PMWS were not observed in any animals of groups 1, 2,
3, and 4 for the duration of the study.
(ii) Gross lesions. All pigs were subjected to necropsy at
DPC 21. The enlargement of lymph nodes of the vaccinated
pigs in groups 1, 2, and 3 generally ranged from mild to mod-
erate, with 1 or 2 pigs with severely enlarged (3 times normal
size) lymph nodes in each group (Table 3). The lymph nodes of
all nonvaccinated group 4 pigs were moderately to severely
enlarged (Table 3). The mean gross lesion scores of the lymph
nodes differed between groups 1, 2, 3, and 4 (P  0.0007). The
values for vaccinated groups 1, 2, and 3 did not differ (P 
0.05) among those groups but were less than the mean score of
the nonvaccinated group 4 pigs (P  0.05; Table 3).
(iii) Microscopic lesions. Microscopic lung lesions charac-
terized as mild peribronchiolar lymphoplasmacytic and histio-
cytic bronchointerstitial pneumonia and liver lesions charac-
terized as mild lymphoplasmacytic hepatitis were detected in
pigs in all groups (Table 4). Mild LD of lymph node follicles
was detected in 4 of 12 group 1 pigs, 1 of 12 group 2 pigs, and
1 of 12 group 3 pigs, and mild to moderate LD was detected in
11 of 12 pigs in group 4 (P  0.001; Table 4). Mild HR of
lymph node follicles was observed in 3 of 12 pigs in group 1 and
1 of 12 pigs in both groups 2 and 3. Mild to moderate HR was
detected in 10 of 12 pigs in group 4 (P  0.001; Table 4). Mild
LD and HR of the tonsil follicles were found in 1 of 12 pigs in
FIG. 1. Quantitative real-time PCR results of determinations of
wild-type PCV2 viral genomic copy loads in TBLN tissues collected
during necropsy at DPC 21 from vaccinated pigs in groups 1, 2, and 3
and from nonvaccinated pigs in group 4. PCV2 DNA was extracted
from 50 g of homogenized TBLN lymph node tissues through the use
of DNAzol reagent and subjected to real-time PCR amplification. Pigs
positive for PCV2 genomic DNA in each group are indicated with an
open circle. The numbers 9, 10, 7, and 3 within circles along the x axis
indicate the numbers of animals in each group that were negative for
PCV2 genomic DNA in the TBLN. The PCV2 genomic copy loads
were determined by real-time PCR and are represented as a log value
of PCV2 genomic copy loads per 10 g of TBLN tissue (y axis).
TABLE 3. Gross lymph node lesions in vaccinated and
nonvaccinated pigs
Group Vaccinea Route ofvaccination
No. of pigs
with gross
lymph node
lesions/total
no. of pigsb
1 PCV1-2 DNA Intramuscular 12/12 (2.0)I
2 PCV1-2 DNA Intralymphoid 12/12 (1.8)I
3 PCV1-2 virus Intramuscular 12/12 (1.6)I
4 None 12/12 (2.7)II
a Animals in group 1 to 3 were vaccinated with chimeric PCV1-2 infectious
DNA clone or chimeric PCV1-2 live virus. At 42 DPV, all animals in groups 1 to
4 were challenged with wild-type pathogenic PCV2.
b All 12 pigs in each group were subjected to necropsy at 21 DPC. Results
represent the number of animals with enlarged lymph nodes/number of animals
in each group (numbers in parentheses represent mean scores of estimated
enlargement). Different superscripts Roman numerals (I and II) indicate differ-
ent mean value scores between groups (P  0.05).
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group 1, 0 of 24 pigs in groups 2 and 3, and 7 of 12 pigs in group
4 (P  0.0003; Table 4). Mild LD and HR of the spleen
follicles were observed in 2 of 12 pigs in group 1 and in none
of the pigs in groups 2 and 3, but 10 of 12 group 4 pigs
exhibited mild to moderate LD and 9 of 12 group 4 pigs
exhibited mild to moderate HR (P  0.0001; Table 4). Results
with respect to the presence of lesions in other tissues and
organs are summarized in Table 4.
(iv) Detection of PCV2 antigen. At necropsy (DPC 21),
PCV2 antigen was not detected in the lymph node tissues of
pigs in vaccinated groups 1, 2, and 3 except for one pig in group
3. In the nonvaccinated group 4 pigs, low-to-high amounts of
PCV2 antigen were detected in the lymph nodes (P  0.0001;
Table 5). No PCV2 antigen was detected in the tonsil of group
1, 2, and 3 pigs. However, low-to-high amounts of PCV2 anti-
gen were detected in the tonsil of 8 of 12 nonvaccinated group
4 pigs (P 0.0001; Table 5). PCV2 antigen was not detected in
spleen tissues of vaccinated group 1, 2, or 3 pigs. Low-to-
moderate amounts of PCV2 antigen were detected in the
spleen tissue of 5 of 12 pigs in nonvaccinated group 4 (P 
0.002; Table 5). No PCV2 antigen was detected in thymus
tissues of any pigs (Table 5).
DISCUSSION
PMWS has become a serious global pig disease; hence, there
is an urgent need for the development of a vaccine against
PCV2-associated diseases, including PMWS. Fenaux et al. pre-
viously reported that a chimeric PCV1-2 virus is attenuated
when inoculated into SPF pigs but is capable of inducing a
humoral immune response against PCV2 capsid protein, sug-
gesting that the chimeric PCV1-2 may serve as a candidate
vaccine against PCV2 infection (11). In this study, we demon-
strated that pigs vaccinated with the chimeric PCV1-2 candi-
date vaccine developed protective immunity against wild-type
pathogenic PCV2 challenge. We also demonstrated that pigs
can be effectively vaccinated using an intramuscular route by
injections with both the infectious chimeric PCV1-2 DNA
clone and chimeric PCV1-2 live virus.
The majority of the vaccinated pigs in all 3 groups serocon-
verted to PCV2 antibodies within 4 to 6 weeks postvaccination.
The remaining seronegative pigs at the time of challenge had
elevated PCV2 antibody titers with rising S/P ratios. Statistical
analysis showed that there is a significant overall vaccine effect
on S/P ratios (P  0.004). No chimeric PCV1-2 viremia was
detected throughout the study in the vaccinated pigs, which is
in agreement with our earlier study (11). Most importantly, no
PCV2 viremia was detected in vaccinated pigs after challenge
with wild-type pathogenic PCV2. In contrast, PCV2 viremia
was detected in 9 of 12 nonvaccinated pigs after challenge.
After PCV2 challenge, PCV2 antigen was detected in low-to-
high amounts in lymph node, tonsil, and spleen tissues of
nonvaccinated pigs but not in the vaccinated pigs with the
exception of one pig in group 3. Vaccinated pigs also had
reduced PCV2 genomic copy viral loads in the lymph nodes.
These data indicate that the chimeric PCV1-2 candidate vac-
cine can prevent PCV2 viremia and significantly reduce the
amount of PCV2 virus in the lymphoid tissues, which are im-
portant factors in pathogenesis of PCV2-associated diseases.
The mean scores of microscopic lesions in lymph node,
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spleen, and tonsil tissues of the three vaccinated groups
showed that the lesions were less severe (P  0.05) than those
of the nonvaccinated group, indicating protection against
PCV2 challenge by the candidate vaccine. The vaccinated pigs
had significantly less enlargement of lymph nodes than the
nonvaccinated pigs. The enlargement of the lymph nodes ob-
served in vaccinated pigs may be attributed to normal vaccine
activation of the immune system in response to the PCV2
challenge, since the enlarged lymph nodes in vaccinated pigs
had no detectable microscopic lesions or viral DNA. In non-
vaccinated pigs, LD and HR of follicles associated with PCV2
antigen were observed in lymph node, spleen, and tonsil con-
sistent with the hallmark PCV2-associated pathological lesions
observed in natural and experimental cases of PMWS. In con-
trast, only one of the vaccinated pigs had detectable PCV2
antigen in lymphoid tissues. These results strongly indicate that
chimeric PCV1-2 candidate vaccine is effective in protecting
pigs from PCV2-associated lymphoid lesions and thus in pre-
venting the detrimental effects on the immune system.
The occurrence of LD during initial PCV2 infection may be
linked to the eventual occurrence of leukopenia prior to the
onset of clinical PMWS (26, 32). Therefore, the chimeric
PCV1-2 candidate vaccine may have the ability to stop the
eventual progression to clinical PMWS by preventing the ini-
tial LD of lymphoid tissues.
No significant differences were found among the three dif-
ferent routes of vaccination with the PCV1-2 candidate vac-
cine. Intramuscular vaccination with PCV1-2 DNA clone, in-
tralymphoid vaccination with PCV1-2 DNA clone, and
intramuscular vaccination with PCV1-2 live virus were all ef-
fective in inducing protective immunity against PCV2 infec-
tion. However, the intramuscular vaccination route is the only
route likely to be acceptable to swine producers. The intralym-
phoid route of vaccination with chimeric PCV1-2 infectious
DNA clone was included as a positive control, since Fenaux et
al. had previously shown that this route has the ability to
induce an infection (9, 11).
Low levels of maternal antibody found in a few animals in
groups 1, 2, and 3 had no apparent effect on the induction of
protective immunity by the chimeric PCV1-2 candidate vac-
cine. Since there were only a few animals with low levels of
maternal antibodies in this study, a definitive answer cannot be
given to the question of whether or not the low level of ma-
ternal antibodies has any effect on vaccination with a live
vaccine. Since many newborns in commercial swine farms have
PCV2 maternal antibodies following colostrum uptake, future
studies with larger numbers of animals with different levels of
maternal antibody are warranted to confirm our preliminary
results.
Although not all the vaccinated animals seroconverted to
PCV2 by the time of challenge, they were all protected against
the pathogenic PCV2 challenge, suggesting that high S/P ratios
of PCV2 antibody responses are not absolutely required for
protection. It is possible that the chimeric PCV1-2 candidate
vaccine induces a cell-mediated immune response (8), which
may be equally or more important for induction of protection
against PCV2. Further research is warranted to determine the
exact role and the extent of cell-mediated immunity induced by
the candidate vaccines in protection against PCV2 infections.
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